KMT2A and acute myeloid leukemia: Co-treatment with ziftomenib and venetoclax also displayed synergistic lethal activity against PD AML cells harboring MLL-AF9 (sample #3), mtNPM1 (sample #11) and mtNPM1 plus FLT3-ITD and FLT3-TKD (sample #4) (Fig. 2A, B, and Supplementary Figs. S6F–S6H).